Multi-regional multi-omics analysis for tumor heterogeneity prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining intra-tumoral heterogeneity in clear cell renal cell carcinoma (ccRCC) are inadequate in predicting the efficacy of immune checkpoint inhibitor (ICB) therapy, as they fail to accurately assess the complex genomic, transcriptomic, and immunological variations within the tumor microenvironment.
Innovation Solution
A method involving multi-regional multi-omics analysis is employed to determine a weighted genome instability index (wGII) and intra-tumoral heterogeneity index (ITH), which classifies tumor regions based on mutational frequency and analyzes parameters like neoantigen heterogeneity, immune cell signatures, and myeloid activity to predict ICB therapy outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for determining intra-tumoral heterogeneity are used, then the assessment process is simple, but the accuracy of predicting ICB therapy efficacy is insufficient
Solution Approach 1:
The tumor microenvironment is divided into multiple spatial regions, and each region is analyzed separately for genomic instability index and intra-tumoral heterogeneity. This segmentation allows for capturing the spatial variability and complexity of the TME, thereby improving the accuracy of ICB therapy prediction by considering regional differences rather than treating the tumor as a homogeneous entity.
Solution Approach 2:
The analysis transitions from traditional single-dimensional biomarker assessment to multi-dimensional evaluation by integrating multiple omics layers (genomic, transcriptomic, proteomic) across multiple spatial regions. This dimensional expansion captures the complexity of TME heterogeneity more comprehensively, enabling more accurate prediction of ICB therapy response.
2Loss of information
If multi-regional multi-omics analysis is performed, then comprehensive TME characterization is achieved, but the time and resources required increase
Solution Approach 1:
The method performs preliminary classification of tumor regions based on weighted genome instability index (wGII) before conducting full multi-omics analysis. By pre-identifying regions with high genomic instability that are more likely to exhibit significant ITH, the approach prioritizes analytical resources on the most informative regions, reducing overall analysis time while maintaining comprehensive characterization of clinically relevant TME heterogeneity.
Solution Approach 2:
Instead of applying uniform multi-omics analysis across all tumor regions, the method applies different analytical depths to different regions based on their wGII classification. Regions with high wGII receive more intensive multi-omics profiling, while regions with low wGII receive streamlined analysis, optimizing resource allocation while preserving essential TME characterization information.
Data Source
AI summary
Described is a multi-regional, multi-omics approach to uncovering the mechanisms of immune escape in carcinoma. Immunotherapy with ant-PD1 and anti-CTLA4 elicits a heterogeneous immunological response across different regions of the tumor. Several genetic alterations associated with high intra-tumoral heterogeneity (ITH) shape tumor microenvironment (TME).